...
首页> 外文期刊>Life sciences >Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein.
【24h】

Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein.

机译:环孢菌素A在表达高水平P-糖蛋白的细胞中作为钙调神经磷酸酶抑制剂的效能较低。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cyclosporin A (CsA) is a widely-used immunosuppressant drug whose therapeutic and toxic actions are mediated through inhibition of calcineurin (CN), a calcium- and calmodulin-dependent phosphatase. Inhibition of CN by CsA requires drug binding to its protein cofactor in the inhibition, cyclophilin. Because cyclophilin is a high affinity target for CsA it is expected that this protein can act as a reservoir for the drug in the cell and may be able to inhibit cellular efflux of CsA. P-glycoprotein (P-gp) is known to increase the rate of CsA efflux from CsA loaded cells but it is not clear if the P-gp drug efflux pump can compete effectively with cyclophilin at therapeutically relevant concentrations of CsA. To test the hypothesis that increased expression of P-gp confers protection against CsA-dependent inhibition of CN phosphatase activity, KB-V cells expressing varying levels of P-gp were analyzed to determine the potency of CsA as a CN inhibitor. When intact cells were treated with CsA, a positive correlation was observed between P-gp expression and resistance to CsA-dependent inhibition of CN: the IC50 is approximately 20-fold higher in the multidrug resistant epidermal carcinoma cell line, KB-V, which expresses P-gp at a high level than in the parental, KB, cell line expressing very low levels of P-gp. The resistance displayed by KB-V cells is abrogated by co-administration of the P-gp inhibitor verapamil, whereas verapamil has no effect on CsA potency in control KB cells. In cell lysates from KB-V cells with different amounts of P-gp CsA exhibits equivalent potency, indicating that the difference in sensitivity to CsA among the cell types requires maintenance of cell integrity. These observations support the view that resistance to CN inhibition by CsA occurs in cells with moderately elevated P-gp activity. Therefore, P-gp activity appears to be an important determinant of CsA cellular specificity for both therapeutic and toxic effects.
机译:环孢菌素A(CsA)是一种广泛使用的免疫抑制剂,其治疗和毒性作用是通过抑制钙调磷酸酶(CN)(一种钙和钙调蛋白依赖性磷酸酶)介导的。 CsA对CN的抑制作用需要药物与其蛋白质辅因子结合,即亲环蛋白。由于亲环蛋白是CsA的高亲和力靶标,因此可以预期该蛋白可以充当细胞中药物的储库,并可能抑制CsA的细胞外排。已知P-糖蛋白(P-gp)会增加CsA负载细胞的CsA外排率,但是尚不清楚P-gp药物外排泵是否可以在治疗相关浓度的CsA上与亲环蛋白有效竞争。为了检验P-gp表达增加可保护CsA依赖性抑制CN磷酸酶活性的假说,分析了表达不同水平P-gp的KB-V细胞以确定CsA作为CN抑制剂的效力。当用CsA处理完整细胞时,观察到P-gp表达与对CNs的CsA依赖性抑制的抗性之间呈正相关:在具有多重耐药性的表皮癌细胞系KB-V中,IC50大约高20倍。 P-gp的表达水平高于亲本KB细胞中P-gp的水平。通过共同施用P-gp抑制剂维拉帕米可消除KB-V细胞表现出的抗药性,而维拉帕米对对照KB细胞中CsA效能无影响。在具有不同量P-gp CsA的KB-V细胞裂解物中,CsA表现出同等效力,这表明细胞类型之间对CsA敏感性的差异要求维持细胞完整性。这些观察结果支持这样的观点,即在具有适度升高的P-gp活性的细胞中发生了对CsA的CN抑制的抗性。因此,P-gp活性似乎是CsA细胞特异性治疗和毒性作用的重要决定因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号